Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Quince Therapeutics, Inc. - Common Stock (NQ: QNCX ) 0.7800 -0.0013 (-0.17%) Streaming Delayed Price Updated: 2:57 PM EDT, Sep 27, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 63,885 Open 0.7603 Bid (Size) 0.7700 (9) Ask (Size) 0.8000 (13) Prev. Close 0.7813 Today's Range 0.7601 - 0.8000 52wk Range 0.5116 - 1.430 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Quince Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference September 03, 2024 From Quince Therapeutics, Inc. Via Business Wire Why Xperi Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket August 19, 2024 Via Benzinga Performance YTD -25.00% -25.00% 1 Month +13.04% +13.04% 3 Month +9.06% +9.06% 6 Month -26.42% -26.42% 1 Year -33.33% -33.33% More News Read More Why Greenland Technologies Shares Are Trading Higher By Around 40%; Here Are 20 Stocks Moving Premarket August 16, 2024 Via Benzinga Quince Therapeutics Announces The Lancet Neurology Publication of Phase 3 ATTeST Clinical Trial Data Evaluating EryDex for the Treatment of Ataxia-Telangiectasia (A-T) August 15, 2024 From Quince Therapeutics, Inc. Via Business Wire QNCX Stock Earnings: Quince Therapeutics Reported Results for Q2 2024 August 13, 2024 Via InvestorPlace Quince Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results August 13, 2024 From Quince Therapeutics, Inc. Via Business Wire Quince Therapeutics Announces First Patient Dosed in Phase 3 Clinical Trial of EryDex for the Treatment of Ataxia-Telangiectasia June 25, 2024 From Quince Therapeutics, Inc. Via Business Wire Quince Therapeutics Receives U.S. FDA Fast Track Designation for EryDex System June 03, 2024 From Quince Therapeutics, Inc. Via Business Wire QNCX Stock Earnings: Quince Therapeutics Reported Results for Q1 2024 May 13, 2024 Via InvestorPlace Quince Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results May 13, 2024 From Quince Therapeutics, Inc. Via Business Wire Quince Therapeutics to Present at The Citizens JMP Life Sciences Conference May 06, 2024 From Quince Therapeutics, Inc. Via Business Wire QNCX Stock Earnings: Quince Therapeutics Reported Results for Q4 2023 April 02, 2024 Via InvestorPlace Quince Therapeutics Provides Business Update and Reports Fourth Quarter and Fiscal 2023 Financial Results April 01, 2024 From Quince Therapeutics, Inc. Via Business Wire Quince Therapeutics Launches Scientific Advisory Board February 22, 2024 From Quince Therapeutics, Inc. Via Business Wire Quince Therapeutics Appoints Former Reata Pharmaceuticals Chief R&D Officer Dr. Rajiv Patni to its Board of Directors February 15, 2024 From Quince Therapeutics, Inc. Via Business Wire Quince Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference February 07, 2024 From Quince Therapeutics, Inc. Via Business Wire Quince Therapeutics to Participate at Investor Events in January 2024 January 04, 2024 From Quince Therapeutics, Inc. Via Business Wire SHF Holdings And 3 Other Stocks Under $2 Insiders Are Buying December 08, 2023 Via Benzinga Topics Stocks Exposures US Equities Over $2M Bet On This Industrial Stock? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying December 04, 2023 Via Benzinga Topics Stocks Exposures US Equities Quince Therapeutics Completes Acquisition of EryDel S.p.A. October 23, 2023 From Quince Therapeutics, Inc. Via Business Wire Why Glimpse Group Shares Are Trading Lower By Around 41%; Here Are 20 Stocks Moving Premarket September 29, 2023 Via Benzinga U.S. FDA Partial Clinical Hold Lifted on IND for EryDel’s Lead Phase 3 Asset EryDex for the Treatment of Ataxia-Telangiectasia September 28, 2023 From Quince Therapeutics, Inc. Via Business Wire Quince Therapeutics Appoints Dr. Charles S. Ryan as President September 06, 2023 From Quince Therapeutics, Inc. Via Business Wire Quince Therapeutics And 2 Other Stocks Under $3 Insiders Are Buying August 14, 2023 Via Benzinga Topics Stocks Exposures US Equities Quince Therapeutics to Present at Sidoti Virtual Investor Conference on August 17, 2023 August 10, 2023 From Quince Therapeutics, Inc. Via Business Wire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
